Needham & Company LLC reaffirmed their buy rating on shares of Biogen (NASDAQ:BIIB – Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. The brokerage currently has a $294.00 target price on the biotechnology company’s stock. Other equities research analysts have also recently issued reports about the company. Canaccord Genuity […]
Biogen Inc. (NASDAQ:BIIB – Free Report) – Research analysts at Wedbush decreased their Q2 2024 earnings per share estimates for shares of Biogen in a report issued on Wednesday, April 24th. Wedbush analyst L. Chico now forecasts that the biotechnology company will post earnings per share of $3.43 for the quarter, down from their previous […]
Biogen Inc. (NASDAQ:BIIB – Free Report) – Equities researchers at Wedbush reduced their Q2 2024 earnings per share estimates for shares of Biogen in a note issued to investors on Wednesday, April 24th. Wedbush analyst L. Chico now anticipates that the biotechnology company will earn $3.43 per share for the quarter, down from their prior […]